Press Releases
Cyntellect Expands Existing Partnership in Japan to Include Distribution of Celigo™ Adherent Cell Cytometer
San Diego
Jul 13, 2010
Cyntellect, Inc., a privately-held life sciences
company commercializing products to advance the study of cell biology,
stem cell research, biopharmaceutical production, and drug discovery,
today announces the availability of the Celigo™ Adherent Cell
Cytometer in Japan. Celigo is the Company’s proven platform for
non-invasive in situ live cell imaging, providing unsurpassed speed,
flexibility and precision of cellular analysis across a wide range of
applications. Today’s announcement follows Cyntellect’s recent
distribution deals covering China, Taiwan, South Korea, Singapore,
Malaysia and Thailand. Celigo will be distributed by Cyntellect’s long-standing partner in Japan, Summit Pharmaceuticals International Corporation (SPI). SPI is a global biosciences company with business units focused on distribution of drug discovery support tools, import/export and marketing of pharmaceuticals and other related products, and new drug discovery and consulting services regarding pharmaceutical development and new drug license. In addition to Celigo, SPI also distributes Cyntellect’s LEAP Workstation for laser-enabled analysis and processing in Japan. Cyntellect products are sold and supported directly in North America and Europe through the Company’s own team of sales, scientific and service staff.
Celigo has both brightfield and multi-color fluorescence modules and easy-to-use analysis software that provide extremely detailed cellular and sub-cellular data on each individual cell in the microplate well, whether adherent or non-adherent. Celigo offers a diverse range of real-time and endpoint assays, and its small footprint conserves premium research space. Celigo can analyze cells non-destructively, therefore reducing the risk of cell damage and contamination. The system is capable of label-free analysis of live cells and fluorescence cellular analysis.
“The benefits of the Celigo Cell Cytometer can bridge gaps in the emerging Japanese biotech industry,” said Saiid Zarrabian, Cyntellect’s President and Chief Executive Officer. “The speed and precision provided by the Celigo allows for more communication between the world of academia and industry. We see a tremendous sales opportunity as the Japanese bio sector advances.” Added Mr. Zarrabian, “SPI has built a solid reputation through significant experience with the sale and support of sophisticated capital equipment, knowledge of the cell biology space and established sales, support and service infrastructure. Cyntellect customers will be well served by SPI in this expanded relationship.”
“We are very excited to further strengthen our existing relationship with Cyntellect to now promote Celigo in addition to LEAP to the growing Japanese cell biology market,” said Tsuyoshi Karasawa, SPI’s Vice President, Biosciences Group. “Cyntellect has been a valued commercial partner to help us meet the needs of our customers in the cell biology space. Our customers have been longing for a technology that enables rapid in-situ cell imaging and analysis, and Celigo is a perfect solution for this unmet need in cell biology. We look forward to our continued partnership with Cyntellect and successful commercialization of Cyntellect’s products in Japan for this rapidly growing market.”
About Cyntellect
Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, and stem cell research and drug discovery. The Company’s technology employs in situ, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect’s expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.
Source: Cyntellect Inc
Copyright 2010 Ochre media. All rights reserved.